Barrett Ronald W 4

What Happened
Ronald W. Barrett, a director of Janux Therapeutics (JANX), received equity awards on June 11, 2026: 5,500 restricted stock units (RSUs) and 15,500 derivative awards (total 21,000 shares) at $0.00 per share. These were granted as compensation/awards (transaction code A) rather than purchases or sales, so there was no cash paid or stock sold in this transaction.

Key Details

• Transaction date: 2026-06-11; filing date: 2026-06-12 (filed the next day).
• Price: $0.00 per share (grant/award).
• Shares in this filing: 5,500 RSUs (non-derivative) + 15,500 derivative awards = 21,000 total shares granted.
• Shares owned after transaction: not disclosed in the provided filing summary.
• Footnotes (vesting/terms):
  • F1: The 5,500 RSUs each convert to one share and vest on the earlier of June 11, 2027 or the next annual meeting, subject to continued service.
  • F2: The 15,500 derivative awards vest in equal monthly installments over the 12 months after June 11, 2026, but will be fully vested by the next annual meeting if the director remains in service.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag noted in the summary.

Context
RSUs and similar derivative awards are commonly used as compensation and retention tools for directors and typically do not reflect an immediate cash investment or sale. Because these awards vest over time, they only convert to tradable shares if and when vesting conditions are met; their eventual value depends on Janux’s future stock price. The filing appears timely (next-day) and is informational rather than an actionable buy/sell signal.